This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cogent Biosciences said Monday that its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic mastocytosis. The results mean the drug achieved the goals of a Phase 3 study, but a comparison to a rival treatment from Blueprint Medicines remains muddled. In its study, Cogent’s drug, called bezuclastinib, showed a 24-point improvement in a patient-reported symptoms score, compared to a 15-point improvement for participants given a placebo.
Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve
Flanked by her friends as lawmakers debated the future of a 60-year-old health care plan, Latoya Maddox raised her voice, shouting, “No cuts to Medicaid! No cuts to Medicaid!” The chanting, during a meeting of the House Energy and Commerce Committee on May 13, quickly earned her and her fellow disabled activists in the room a rough escort out by Capitol Police.
Practice pharmacists should build deprescribing into routine care, an exclusive event has heard, with delegates encouraged to stay curious, listen to patients and ask the right questions when faced with complex prescribing decisions. Lelly Oboh, consultant pharmacist for older people at Guy’s and St Thomas’ NHS Trust and overprescribing lead for South East London ICB, […] The post Embrace deprescribing and stay curious in complex cases, pharmacists told appeared first on The Pharmacist.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Veeda Lifesciences, a global contract research organisation (CRO), has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company. The investment is part of Veeda’s strategy to integrate artificial intelligence into its clinical trial operations, with a focus on improving patient recruitment, trial efficiency, and diversity across global markets.
Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.
99
99
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.
Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve
Fette Compacting India, a global leader in tablet production technology, has signed a Memorandum of Understanding (MoU) with Goa College of Pharmacy to upskill students and prepare them for careers in the pharmaceutical industry. The agreement was signed at Goa College of Pharmacy’s campus in Panaji by Ashok Gourish, Managing Director of Fette Compacting India, and Dr Gopalkrishna Rao, Principal of Goa College of Pharmacy.
The US Food and Drug Administration (FDA) has approved the first oral on-demand therapy for acute attacks of hereditary angioedema (HAE) in individuals aged 12 years and older. This rare genetic disease leads to tissue swelling attacks in the body that can be life-threatening. It is caused by a deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system, KalVista Pharmaceuticals shared.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Last fall, a group of experts advising the U.S. Food and Drug Administration debated for two days on how to regulate generative artificial intelligence tools in medicine. One report presented at the meeting showed that a generative AI tool supposedly used by 40% of the radiology practices in the U.S. produced clinically significant errors in one of every 21 reports.
Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve
The government has pledged to ‘transition’ community pharmacy from a dispensing-focused service to offering more clinical services, as part of its long-awaited NHS 10-year plan. Published today, the 168-page blueprint has committed to increasing the role of community pharmacy in the management of long-term conditions, including treatment of obesity, high blood pressure and high cholesterol. […] The post Pharmacies’ clinical services offering to expand under NHS 10-year plan appeared first
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership BiomX phage therapy shows potent effect in cystic fibrosis trial by John Pinching | 9th Jul 2025 | News BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study BiomX has published promising phase 1b/2a trial results in Nature Communications , demonstrating that its phage cocktail B
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Testing is difficult for drugs for rare diseases, and new rules may make it harder for sufferers to obtain life-saving drugs US drug regulators have increasingly signaled a focus on faster approvals and rare diseases, but patients with ultra-rare ailments fear they are falling through the cracks, especially given challenges to conducting clinical trials.
WASHINGTON — Six major medical groups, and a pregnant physician, are suing health secretary Robert F. Kennedy Jr. over changes he made to Covid-19 vaccine recommendations that they say were unlawful and undermine public trust in health care. The suit argues that a May 19 directive signed by Kennedy, which said that the Covid-19 vaccine would no longer be recommended for healthy children and pregnant people , violates decades of policy governing how vaccines are reviewed, approved, an
Pharmacists will staff the government’s new neighbourhood health centres alongside nurses, doctors, social care workers and others, the Prime Minister has announced. Sir Keir Starmer has this evening set out early details of the highly anticipated 10-year plan for the NHS ahead of its publication in the morning – largely focusing on the government’s ambitions […] The post BREAKING: Pharmacists to staff new neighbourhood health centres appeared first on The Pharmacist.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
On June 9, 2025, in a significant and controversial shake-up, US Secretary of Health and Human Services Robert F. Kennedy Jr. dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP), the body responsible for advising the federal government on vaccine safety. This decision has raised alarms among public health experts and stakeholders in the vaccine development community, says GlobalData.
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership VarmX secures US approval to begin phase 3 trial of urgent surgery treatment by John Pinching | 8th Jul 2025 | News New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients Biotech company VarmX has received clearance from the US FDA to begin a phase 3 trial of its lead candida
Over 660 million pilgrims gathered at the Maha Kumbh Mela in Prayagraj, India, this past February, and I’m now seeing the downstream consequences in my California clinic. This year, I’ve treated several Americans who returned ill after ritual bathing in India’s sacred river. Their diagnoses have ranged from typhoid fever and multidrug-resistant E. coli to persistent giardiasis and polymicrobial gastroenteritis.
Weeks into his new role as president and CEO of Bryn Mawr, Pa.-based Main Line Health, Edward Jimenez told Becker’s the five-hospital system — with more than 13,000 employees — is taking steps to stay financially resilient while also hiring more physicians and planning new care sites to improve access. Mr. Jimenez assumed the top leadership role in June and brings nearly 30 years of healthcare leadership experience.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM*) is poised to grow at a compound annual growth rate (CAGR) of 2.0 per cent from $7.6 billion in 2024 to $9.3 billion in 2034, driven by the adoption of triple combination therapy, novel prostacyclin formulations, and the entry of disease-modifying therapies, according to GlobalData.
ARLINGTON, VA — July 7, 2025 — The Alliance for Safe Biologic Medicines (ASBM) today announced the retirement of longtime Board member Doug Badger, and the appointment of two new members to its Board of Directors: Cristina V. Beato, MD, and Chris Downing, both of whom previously served in senior leadership roles at the U.S. Department of Health and Services (HHS) from 2001 to 2008.
Recently, the Department of Health and Human Services floated new standards for vaccine approvals, rescinded longstanding Covid-19 vaccine recommendations for healthy children and pregnant women, and fired all 17 members of the Centers for Disease Control and Prevention’s vaccine advisory committee. These actions represent a significant shift in the federal government’s approach to vaccine policy and the safeguarding of the public’s health.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Actithera closes $75.5m Series A to advance radioligand therapy platform by John Pinching | 9th Jul 2025 | News Funding to support lead candidate targeting FAP and pipeline expansion Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead radioli
Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03 per cent and 0.06 per cent, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03 per cent and 0.06 per cent are bioequivalent to Atrovent Nasal Spray, 0.03 per cent and 0.06 per cent, of Boehringer Ingelheim Pharmaceuticals. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03 per cent is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennia
82
82
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
260 
Let's personalize your content